Attached files
file | filename |
---|---|
8-K - Altimmune, Inc. | v200482_8k.htm |
EX-5.1 - Altimmune, Inc. | v200482_ex5-1.htm |
EX-1.1 - Altimmune, Inc. | v200482_ex1-1.htm |
EX-1.2 - Altimmune, Inc. | v200482_ex1-2.htm |
EX-99.1 - Altimmune, Inc. | v200482_ex99-1.htm |
Contact:
Stacey
Jurchison
PharmAthene,
Inc.
Phone:
410-269-2610
Stacey.Jurchison@PharmAthene.com
PharmAthene
Announces Pricing of $15 Million Public Offering
ANNAPOLIS,
Md., Oct 29, 2010 /PRNewswire via COMTEX/ — PharmAthene, Inc. (NYSE Amex:
PIP) ("PharmAthene" or the "Company"), a biodefense company developing medical
countermeasures against biological and chemical threats, today announced that it
has priced a registered public offering of 4,300,000 shares of its common stock
at a price to the public of $3.50 per share.
The
Company expects that the offering will yield net proceeds, before expenses, of
approximately $14.1 million and intends to use the net proceeds of the offering
for repayment of debt and general corporate purposes.
Roth
Capital Partners, LLC served as sole underwriter for the offering. Noble
Financial Capital Markets served as the Company's financial advisor in
connection with the offering. In connection with the offering, the Company also
granted the underwriter a 30-day option to purchase up to an additional 645,000
shares to cover over-allotments, if any. The offering is expected to close on or
about November 3, 2010, subject to satisfaction of customary closing
conditions.
The
securities described above are being offered by PharmAthene pursuant to a
registration statement previously filed and declared effective by the Securities
and Exchange Commission on February 13, 2009. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction. The
securities may be offered only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. Copies of
the prospectus and the final prospectus supplement may be obtained, when
available, at the Securities and Exchange Commission's website at
http://www.sec.gov/. Copies of the prospectus and the final prospectus
supplement may also be obtained from Roth Capital Partners, LLC Equity Capital
Markets, 24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and
Rothecm@roth.com.
About
PharmAthene, Inc.
PharmAthene
was formed to meet the critical needs of the United States and its allies by
developing and commercializing medical countermeasures against biological and
chemical weapons. PharmAthene's lead product development programs
include:
*
SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax
vaccine
*
Valortim(R) - a fully human monoclonal antibody for the prevention and treatment
of anthrax infection
*
Countermeasures for nerve agent poisoning by organophosphate compounds,
including nerve gases and pesticides, whose active ingredient is the recombinant
enzyme (butyrylcholinesterase) (or "rBChE").
Statement
on Cautionary Factors
Except
for the historical information presented herein, matters discussed may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including statements
preceded by, followed by, or that include the words "potential"; "believe";
"anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should";
"will"; "project"; "potential"; or similar statements are forward-looking
statements. PharmAthene disclaims any intent or obligation to update these
forward-looking statements other than as required by law. Risks and
uncertainties include risk associated with the reliability of the results of the
studies relating to human safety and possible adverse effects resulting from the
administration of the Company's product candidates, unexpected funding delays
and/or reductions or elimination of U.S. government funding for one or more of
the Company's development programs, the award of government contracts to our
competitors, unforeseen safety issues, challenges related to the development,
scale-up, technology transfer, and/or process validation of manufacturing
processes for our product candidates, unexpected determinations that these
product candidates prove not to be effective and/or capable of being marketed as
products, challenges related to the implementation of our NYSE Amex compliance
plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K
and 10-Q under the caption "Risk Factors" and in its other reports filed with
the U.S. Securities and Exchange Commission (the "SEC"). In particular, there
can be no assurance that PharmAthene will satisfy the NYSE Amex continuing
listing standards by January 26, 2012, or that during the compliance period the
Exchange will not deem PharmAthene's progress toward compliance
inadequate.
Copies of
PharmAthene's public disclosure filings are available from its investor
relations department and our website under the investor relations tab at
www.PharmAthene.com.
SOURCE
PharmAthene, Inc.
- 2
-